Mon panier

LAIR-1

LAIR-1 Informations sur la molécule

Nom anglaisLeukocyte-associated immunoglobulin-like receptor 1Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleImmunoglobulin Heavy Chain Variable Region,HLAIR1,LAIR1,Leukocyte Associated Immunoglobulin Like Receptor 1,CD305 Antigen,hLAIR1,CD305,Leukocyte-Associated Ig-Like Receptor 1
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisLeukocyte-associated immunoglobulin-like receptor 1
Alias de la cibleImmunoglobulin Heavy Chain Variable Region,HLAIR1,LAIR1,Leukocyte Associated Immunoglobulin Like Receptor 1,CD305 Antigen,hLAIR1,CD305,Leukocyte-Associated Ig-Like Receptor 1
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

LAIR-1 Liste de produits

  • Attribut

    Protein (8)

  • Bibliothèque de produits

    En ligne (8)

  • Espèces

    Human (5)Rhesus macaque (1)Mouse (2)

  • Étiquette

    His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (3)Fc Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (6)Biotin-labeled (2)

LAIR-1Contexte de la molécule

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is constitutively expressed on the majority of human peripheral blood mononuclear leukocytes. LAIR-1 or CD305 is a transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory motifs. LAIR-1 recruits SHP-1 and SHP-2 phosphatases upon activation, and cross-linking of the LAIR-1 antigen on natural killer (NK) cells results in strong inhibition of NK cell–mediated cytotoxicity. Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation.Diseases associated with LAIR1 include Chronic Active Epstein-Barr Virus Infection and Palindromic Rheumatism.

LAIR-1Alias de la molécule

LAIR1,CD305

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NC-410NC-410Phase 2 ClinicalNextcure IncColorectal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
NGM-438NGM-438Phase 1 ClinicalMerck & Co Inc, NGM Biopharmaceuticals IncBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques